October 3rd 2024
Acalabrutinib, a BTK inhibitor, has shown promising results in treating mantle cell lymphoma, with the FDA granting it priority review.
September 20th 2024
September 19th 2024
September 18th 2024
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Fisch Highlights Patient Case of Relapse Following Gilteritinib Treatment in FLT3-TKD+ AML
November 29th 2019Following the FDA’S approval of gilteritinib in November 2018, adult patients with FLT3-mutant acute myeloid leukemia were able to receive the FLT3 tyrosine kinase inhibitor when they relapsed or became refractory to a prior therapy. The agent has demonstrated promising efficacy in the population of patients with AML harboring FLT3 mutations.
Read More
MRTX849 Shows Safety, Tolerability in Treating KRAS G12C
November 29th 2019In patients whose solid<strong> </strong>tumors harbor a mutation in <em>KRAS </em>G12C, therapy with MRTX849 has produced promising responses and acceptable toxicity across 3 tumors types, according to data presented at the 2019 American Association for Cancer Research–National Cancer Institute–European Organization for Research and Treatment of Cancer International Conference on Molecular Targets and Cancer Therapeutics.
Read More
Contemporary Therapy for Advanced-Stage Hodgkin Lymphoma
November 27th 2019Hodgkin lymphoma represents approximately 10% of all cases of malignant lymphoma. This group of diseases most commonly affects adolescent and young adults, although approximately 20% to 25% of patients are aged ≥60 years at diagnosis. Advanced-stage disease is generally classified as Ann Arbor stage III to IV, but clinical trials often incorporate patients with high-risk stage II disease, such as those with B symptoms, multiple sites, or bulky disease
Read More
Age Impacts Treatment Options for Patients With CLL
November 21st 2019Kanti R. Rai, MD, professor of medicine, Northwell Health and Zucker School of Medicine at Hofstra University, explains the importance of attention to age when treating patients with chronic lymphocytic leukemia, which is a typically elderly patient population.
Watch
Optimizing Use of Prognostic Markers for the Treatment of CLL
November 20th 2019In an interview with Targeted Oncology at the 2019 Chemotherapy Foundation Symposium, Richard R. Furman, MD, reviewed his presentation on prognostic markers and their importance in the treatment of patients with chronic lymphocytic leukemia.
Read More
Resistance Mutations Pose Complex Challenges for Pathologists
November 13th 2019The emergence of resistance mutations in patients with cancer who receive targeted therapies is an expected development that will require new diagnostic methods of identifying the mechanisms through which these alterations occur, according to Fei Dong, MD, during the 2019 Association for Molecular Pathology Annual Meeting.<br />
Read More
Ibrutinib/Rituximab Seeking Approval As Frontline Treatment for CLL
November 13th 2019A supplemental New Drug Application for the combination of ibrutinib and rituximab has been submitted to the FDA for the first-line treatment of patients aged 70 years or younger with chronic lymphocytic leukemia or small lymphocytic lymphoma, according to a press release from ibrutinib developer, AbbVie.
Read More
The Importance of Molecular Monitoring in the Treatment of AML
November 13th 2019In an interview with Targeted Oncology, Eytan M. Stein, MD, reviews the current treatment landscape of acute myeloid leukemia, underscores the importance of molecular monitoring, and highlights where the field is headed.
Read More
Fisch Highlights Patient Case of Relapse Following Gilteritinib Treatment in FLT3-TKD+ AML
November 8th 2019At the 2019 Association for Molecular Pathology Annual Meeting and Expo, Adam Fisch, MD, PhD, presented a unique patient case where a patient with acute myeloid leukemia harboring a <em>FLT3</em>-TKD mutation lost the mutation following relapse on gilteritinib.<br />
Read More
Dynamic Tumor Cell Profiling Technique Correlates With Therapy Responses
November 8th 2019A technique involving BH3 profiling is emerging as a promising drug discovery tool for assessing whether a tumor is primed for cell death and would respond to anticancer therapy, according to a presentation at the 2019 Association for Molecular Pathology Annual Meeting.
Read More
Results from Phase III Study of Gilteritinib Versus Chemotherapy Published in NEJM
November 4th 2019Detailed results of the phase III ADMIRAL trial, which evaluated the use of gilteritinib in adult patients with FLT3 mutation–positive relapsed or refractory acute myeloid leukemia, have been published in the New England Journal of Medicine and reaffirm the improved overall survival rate seen with gilteritinib compared with chemotherapy in these patients, according to a press release from Astellas Pharma Inc.
Read More
A Look Back at FDA News from October 2019
November 1st 2019In October 2019, the FDA approved a new treatment option for patients with advanced ovarian, fallopian tube, or primary peritoneal cancer, as well as a new dosing regimen for patients receiving moderately emetogenic chemotherapy. Additionally, the FDA granted breakthrough therapy designations to 2 therapies, as well as an orphan drug designation, a priority review, and 2 fast track designations.
Read More
Frankfurt Discusses Complications Arising During the Treatment of GVHD
October 31st 2019During a recent Targeted Oncology live case-based peer perspectives event, Olga Frankfurt, MD, discussed the complications that could development during the treatment of patients with graft-vs-host disease. Frankfurt explained these complications in the context of a patient who develops acute GVHD after undergoing hematopoietic cell transplant.
Read More
Real-World Data Confirm Superiority of Tafasitamab/Lenalidomide Regimen in R/R DLBCL
October 31st 2019Topline results from Re-MIND, an observational retrospective study, demonstrated that the combination of tafasitamab with lenalidomide had a statistically significant and superior objective response rate compared with lenalidomide monotherapy in patients with relapsed/refractory diffuse large B-cell lymphoma who were not eligible for high-dose chemotherapy and stem cell transplant, announced MorphoSys AG, the manufacturer of tafasitamab, in a press release.
Read More
SY-1425 Plus Azacitidine Continues to Show Durable Activity in RARA+ AML
October 25th 2019In the phase II biomarker-driven trial combining retinoic acid receptor alpha agonist SY-145 with azacitidine, newly diagnosed adult patients with RARA-positive acute myeloid leukemia who were unfit for intensive chemotherapy continued to show responses to the combination and demonstrate tolerability of the regimen, according to a press release from Syros Pharmaceuticals.
Read More
Long-Term Ublituximab Plus Ibrutinib Results Show PFS Benefit in High-Risk CLL
October 25th 2019Ublituximab in combination with ibrutinib demonstrated a benefit in progression-free survival over ibrutinib monotherapy, as assessed by an independent review committee, in patients with high-risk relapsed or refractory chronic lymphocytic leukemia in the final long-term results of the phase III GENUINE trial.
Read More
Selecting the Appropriate Patients for Targeted Therapies in Acute Myeloid Leukemia
October 23rd 2019John DiPersio, MD, PhD, discusses targeted therapies for myeloid malignancies using DARTs, Bites, and antibody–drug conjugates, a topic he presented during the 2019 Society for Hematologic Oncology Annual Meeting.
Watch
FDA Approves New Aprepitant Dosing Regimen for CINV After MEC
October 23rd 2019The FDA has approved a supplemental New Drug Application for a single dose of aprepitant injectable emulsion for intravenous use in patients receiving moderately emetogenic chemotherapy. The approval expands the dose for aprepitant to include a 130 mg single-dose regimen for the prevention of acute and delayed chemotherapy-induced nausea and vomiting.<br />
Read More
Bemcentinib Granted FDA Fast Track Designation for R/R AML
October 23rd 2019Bemcentinib, a first-in-class AXL inhibitor, has been approved for a fast track designation by the FDA for the treatment of elderly patients with relapsed or refractory acute myeloid leukemia, according to a press release from BerGenBio.<br />
Read More
Frontline Ivosidenib/Azacitidine Combo Shows Early Promising Efficacy in IDH1+ AML
October 19th 2019Ivosidenib in combination with azacitidine demonstrated promising efficacy in addition to being well tolerated in patients with newly diagnosed <em>IDH1</em>-mutant acute myeloid leukemia who were ineligible for intensive chemotherapy.
Read More
FDA Approves Romiplostim for Earlier Use in Adults With ITP
October 18th 2019The FDA has approved a supplemental biologics license application for an updated indication expanding the use of romiplostim in the treatment of adult patients with immune thrombocytopenia to include newly diagnosed patients and patients with persistent ITP who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy.
Read More
Ruxolitinib Improves ORR in Steroid-Refractory aGVHD in Early Phase III Trial Results
October 16th 2019Ruxolitinib demonstrated a significant improvement in overall response rate over best available therapy at day 28 in patients with steroid-refractory acute graft-versus-host disease, according to topline results from the phase III REACH2 trial. Novartis, the company developing the JAK inhibitor, announced in a press release that this met the primary endpoint of the trial.
Read More